Prescribing Guidelines for Medicinal Drugs and Driving

Chairs: J.J. de Gier and J. Alvarez
Contact the Prescribing Guidelines for Medicinal Drugs and Driving Working Group

 

Goal: To provide guidelines for safe prescribing and dispensing of medicinal drugs to patients who drive, especially in coordination with DRUID. This working group allows ICADTS members to share information and work together in the intervals between conferences.

 

The ICADTS Working Group has been working on the categorisation of the effects of medication on driving for many years. The original Working Group report was published in 2001. That work was continued under the auspices of the European DRUID project.

 

Some European members of the ICADTS Working Group (Alvarez, De Gier, Mercier-Guyon, Verstraete) dedicated their time and effort by joining DRUID Workpackage 4 (WP4).

DRUID completed this work in 2011. The reports can be found in Publications and Deliverables Workpackage 4 at www.bast.de/EN/Traffic_Safety/Subjects/druid/druid.html , These documents are an extensive update of the ICADTS Working Group documents found elsewhere in this website (ICADTS Summary Report and Drug List, Version June 26th, 2007).

 

Medications have a ‘Summary of Product Characteristics’ which is the official document on which the Package Information Leaflet for patients is based. In collaboration with the PharmacoVigilance WorkingParty (PhVWP) of the European Medicines Evaluation Agency (EMA) in London, DRUID WP 4 Partners and EMA experts agreed on a new system of warnings for moderately and severely impairing medicines proposed for improvement of the

 

Further development of these proposals is dependent upon collaboration with EU’s Directorate General for consumer protection and health care (DG Sanco). So far no follow-up activities have occurred since the completion of the work within DRUID (October 2011). New initiatives for international collaboration are needed. ICADTS could play a key-role in developing new world-wide initiatives based on present experiences in some European countries.

 

The Working Group Co-Chairs (Alvarez and De Gier) propose the following activities in order to continue the work:

  1. Invite ICADTS members to join the ICADTS Working Group and to take the opportunity to identify key-persons in their country who have an interest in safer use of medicines by patients who drive.
  2. Update the information on the ICADTS website based on DRUID materials, in particular the medicines list with 3-tier level categories and the prescribing and dispensing guidelines. Adding categorisation of new medicines and updates on existing categorisation of medicines is needed.
  3. Seek for dissemination of ICADTS Working Group Documents to improve prevention, education of patients/drivers, and prescribing and dispensing practices by communication to professional organisations of physicians and pharmacists and share “best practices”.